StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
086060.KQ$3770.00+1.07%
Fair $3770.00+0.0%

086060.KQ

GeneBioTech Co. ,Ltd

Unknown / UnknownKOSDAQ

$3770.00

+40.00 (+1.07%)

Fairly Valued+0.0%Fair Value $3770.00Fund rank 27/100 · Data gapFallback financials|
SA 43/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $3.9B · quality 47.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

43/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists.
Thesis & Journal · 086060.KQLocal privado en este navegador · GeneBioTech Co. ,Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$32.5B

P/E

8.6x

↓

EV/EBITDA

5.9x

↓

ROE

6.9%

↑

Gross Margin

15.8%

↓

Debt/Equity

0.27

↑
52-Week Range$3770
$3600$5990

TradingView lightweight chart

086060.KQ price, volumen y niveles de valoración

Último $3,770Periodo -55.7%
Fair value: $3,770

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+3.1%

FCF CAGR

—

FCF margin

4.2%

FCF / Net income

1.02x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $90.79B · net income $3.79B · FCF $3.85B

2022-FY → 2025-FY

Gross margin

15.8%+3.2% pts

Operating margin

4.4%+2.3% pts

Net margin

4.2%+2.3% pts

FCF margin

4.2%+10.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$90.79B$90.79B$82.96B$79.48B$82.76B
Net Income$3.79B$3.79B$2.87B$2.59B$1.52B
EBITDA$6.36B$6.36B$5.51B$5.29B$3.38B
EPS440.00440.00333.00301.00177.00
Gross Margin15.8%15.8%16.3%17.4%12.7%
Operating Margin4.4%4.4%4.6%5.1%2.1%
Net Margin4.2%4.2%3.5%3.3%1.8%
Balance Sheet
Debt/Equity0.270.270.310.260.28
Cash Flow
Free Cash Flow$3.85B$3.85B$-1.65B$6.60B$-4.85B
Returns
ROE6.9%6.9%5.6%5.4%3.3%
Valuation
P/E8.578.5710.2014.4922.68
EV/EBITDA5.955.956.317.8011.89
P/B0.590.590.570.780.76
Growth & Yield
Revenue Growth9.4%9.4%4.4%-4.0%—
EPS Growth32.1%32.1%10.6%70.1%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-8.7%

fácil

EPS terminal req.

$334.52

Spread vs growth

40.9%

5Y implied EPS CAGR

-1.7%

fácil

EPS terminal req.

$404.77

Spread vs growth

33.8%

10Y implied EPS CAGR

4.0%

fácil

EPS terminal req.

$651.89

Spread vs growth

28.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.5%

Total return

-6.5%

Start / end P/E

12.1x → 8.6x

EPS bridge

333.00 → 440.00

Residual

-9.4%

EPS growth+32.1%
Multiple rerating-29.2%
Dividend+0.0%
Residual / FX / buybacks / cross-term-9.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.